"Mitomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
| Descriptor ID |
D016685
|
| MeSH Number(s) |
D02.806.400.249.350 D03.383.097.500.350 D03.633.100.473.412.249.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mitomycin".
Below are MeSH descriptors whose meaning is more specific than "Mitomycin".
This graph shows the total number of publications written about "Mitomycin" by people in this website by year, and whether "Mitomycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2015 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mitomycin" by people in Profiles.
-
Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in?vivo. Stem Cells Transl Med. 2021 02; 10(2):278-290.
-
Internal Urethrotomy With Intralesional Mitomycin C: An Effective Option for Endoscopic Management of Recurrent Bulbar and Bulbomembranous Urethral Strictures. Urology. 2017 Dec; 110:223-227.
-
Reply: To PMID 26099892. Urology. 2015 Jun; 85(6):1499-500.
-
Visual Internal Urethrotomy With Intralesional Mitomycin C and Short-term Clean Intermittent Catheterization for the Management of Recurrent Urethral Strictures and Bladder Neck Contractures. Urology. 2015 Jun; 85(6):1494-9.
-
Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. FEBS Lett. 2001 Feb 16; 490(3):196-201.
-
Adjuvant therapy for pancreatic adenocarcinoma. J Gastrointest Surg. 2001 Jan-Feb; 5(1):6-7.
-
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys. 2000 Nov 01; 48(4):1089-96.
-
Preventing myringotomy closure with topical mitomycin C in rats. Otolaryngol Head Neck Surg. 1999 Jun; 120(6):794-8.
-
The effect of a selective 5-lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats. Inflammation. 1996 Jun; 20(3):217-27.
-
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. Int J Radiat Oncol Biol Phys. 1996 Mar 01; 34(4):793-802.